# GLP-1 Agonist Clinical Evidence and Cardiovascular Outcomes > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/glp-1-telehealth-market-expansion-clinical-evidence/ > **Published:** 2026-05-13T03:41:03-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T17:00:40-04:00 > **Clinical Summary:** Explore GLP-1 telehealth market expansion and clinical evidence impacting cardiovascular outcomes and prescribing practices in metabolic care. --- GLP-1 Clinical Relevance  #41Contextual Information  Background context; limited direct clinical applicability. ⚕ GLP-1 News  |  CED Clinic CommentaryBusiness Performance AnalysisGLP-1 Weight LossSemaglutidePrimary CareAdult Obesity PopulationRevenue Growth TrajectoryAppetite Regulation TherapyTelehealth Market ExpansionDirect-to-Consumer Pharmaceutical ModelQuarterly Earnings ReportInternational Market Penetration Why This Matters Family medicine clinicians should recognize that sustained telehealth platform growth and market expansion in GLP-1 delivery directly impacts [patient access](https://cedclinic.com/iowa-medical-cannabis-dispensaries-expansion/) patterns and supply chain reliability for their own GLP-1-prescribing practices. Understanding the financial health and operational capacity of major GLP-1 distributors informs clinical decision-making regarding patient referral options, medication availability, and continuity of care coordination in an increasingly fragmented delivery ecosystem. Clinician awareness of market consolidation and competitive dynamics among GLP-1 providers helps identify potential disruptions to formulary access and reimbursement structures that may affect treatment initiation and continuation for their patient populations. Clinical Summary A meaningful clinical summary requires peer-reviewed published research with specific methodological details, patient populations, outcome measures, statistical analyses, and clinical endpoints. Earnings reports and financial news articles do not contain the clinical data necessary to inform prescriber decision-making about GLP-1 therapeutics or metabolic medicine practice. Clinical Takeaway GLP-1 medications have become a significant driver of telehealth growth and patient demand in primary care settings. The expansion of GLP-1 access through digital health platforms reflects increasing consumer interest in pharmacologic [weight management](https://cedclinic.com/cannabis-metabolism-weight-management-science/) alongside lifestyle modification. Family physicians should expect continued growth in GLP-1 utilization, which necessitates robust protocols for patient screening, monitoring, and management of common adverse effects. When discussing GLP-1 therapy with patients, clearly communicate that these medications work best as part of a comprehensive approach including diet and exercise, and that ongoing medication adherence combined with regular follow-up visits optimizes outcomes and safety. Dr. Caplan’s Take “The telehealth sector’s resurgence around GLP-1 therapeutics reflects a genuine clinical opportunity, not just market enthusiasm. What interests me most is how companies like Hims are positioning themselves at the intersection of access and convenience, which frankly addresses real gaps in how we deliver metabolic care to patients who otherwise wouldn’t engage with traditional primary care. However, investors should recognize that sustainable growth in this space depends on clinical outcomes data and proper patient screening, not just prescription volume. In my practice, I’m already seeing patients who initiated GLP-1 therapy through these platforms without baseline metabolic labs or cardiovascular risk stratification, which underscores why physician-directed models still matter when communicating with patients about where and how they obtain these medications.” Clinical Perspective Hims’ Q1 earnings reflect the accelerating mainstream adoption of GLP-1 therapies, which now represent a material revenue driver for telehealth platforms and signals sustained patient demand beyond initial hype cycles. This market expansion underscores the critical need for clinicians to establish direct relationships with patients seeking GLP-1 therapy rather than ceding this patient population to direct-to-consumer models that may lack comprehensive metabolic assessment and longitudinal care coordination. A concrete action: implement a streamlined GLP-1 intake protocol in your practice that documents baseline metabolic markers, screens for contraindications, and establishes measurable clinical goals within the first visit to compete effectively in an increasingly competitive prescribing landscape. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Live%3A%20Hims%20Reports%20Q1%20Earnings%20Tonight.%20Can%20the%20Recovery%20Continue%3F%20-%2024%2F7%20Wall%20S%20%40drcaplan&url=https%3A%2F%2F247wallst.com%2Finvesting%2F2026%2F05%2F11%2Flive-hims-reports-q1-earnings-tonight-can-the-recovery-continue%2F)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2F247wallst.com%2Finvesting%2F2026%2F05%2F11%2Flive-hims-reports-q1-earnings-tonight-can-the-recovery-continue%2F)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Live%3A%20Hims%20Reports%20Q1%20Earnings%20Tonight.%20Can%20the%20Recovery%20Continue%3F%20-%2024%2F7%20Wall%20S%20--%20via%20%40drcaplan.bsky.social%20https%3A%2F%2F247wallst.com%2Finvesting%2F2026%2F05%2F11%2Flive-hims-reports-q1-earnings-tonight-can-the-recovery-continue%2F)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [Read full article at 247wallst](https://247wallst.com/investing/2026/05/11/live-hims-reports-q1-earnings-tonight-can-the-recovery-continue/) Nationwide GLP-1 Care Looking for thoughtful, physician-led GLP-1 guidance? CED Clinic offers GLP-1 and metabolic guidance across the United States, including evaluation, prescribing support, side-effect management, and longer-term follow-up for people seeking careful, personalized care. [Learn More](https://cedclinic.com/metabolic/) [Book Now](https://book.squareup.com/appointments/kn3vehwoiz6to6/location/DPV0VF8Y74WA7/services) Table of Contents - [FAQ](#FAQ)[What are GLP-1 drugs and why are they becoming so popular?](#What_are_GLP-1_drugs_and_why_are_they_becoming_so_popular) - [Are GLP-1 medications only for people with diabetes?](#Are_GLP-1_medications_only_for_people_with_diabetes) - [How much weight can I expect to lose with GLP-1 therapy?](#How_much_weight_can_I_expect_to_lose_with_GLP-1_therapy) - [What are the common side effects of GLP-1 medications?](#What_are_the_common_side_effects_of_GLP-1_medications) - [How long do I need to take GLP-1 medication?](#How_long_do_I_need_to_take_GLP-1_medication) - [Can I stop taking GLP-1 medication once I reach my weight loss goal?](#Can_I_stop_taking_GLP-1_medication_once_I_reach_my_weight_loss_goal) - [Are GLP-1 drugs safe for long-term use?](#Are_GLP-1_drugs_safe_for_long-term_use) - [What is the cost of GLP-1 therapy?](#What_is_the_cost_of_GLP-1_therapy) - [How does GLP-1 therapy compare to weight loss surgery?](#How_does_GLP-1_therapy_compare_to_weight_loss_surgery) - [Will my weight loss be permanent after GLP-1 treatment?](#Will_my_weight_loss_be_permanent_after_GLP-1_treatment) - [Related](#Related) ## FAQ #### What are GLP-1 drugs and why are they becoming so popular? GLP-1 drugs are medications that help manage blood sugar and reduce appetite, leading to weight loss in many patients. They have become popular because they offer significant health benefits for [weight management](https://cedclinic.com/cannabis-metabolism-weight-management-science/) and diabetes control with relatively good tolerability. #### Are GLP-1 medications only for people with diabetes? No, GLP-1 medications can be prescribed for weight management in people without diabetes who meet certain criteria. However, they are also highly effective for treating type 2 diabetes and improving [cardiovascular health](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/). #### How much weight can I expect to lose with GLP-1 therapy? Weight loss varies by individual, but clinical studies show patients typically lose 10 to 22 percent of their body weight depending on the specific medication and adherence. Results depend on factors like your starting weight, diet, exercise, and how well you respond to the medication. #### What are the common side effects of GLP-1 medications? The most common [side effects](https://cedclinic.com/cannabis-intoxication-memory-disruption/) include nausea, vomiting, constipation, and diarrhea, which typically improve over time as your body adjusts. These effects are usually mild to moderate and tend to decrease after the first few weeks of treatment. #### How long do I need to take GLP-1 medication? GLP-1 therapy is typically a long-term treatment because weight regain often occurs after stopping the medication. Your doctor will help determine the appropriate duration based on your health goals and individual response. #### Can I stop taking GLP-1 medication once I reach my weight loss goal? Stopping GLP-1 medication usually results in weight regain over time, so most patients benefit from continuing treatment as a maintenance therapy. Your doctor can discuss the best approach for your specific situation and goals. #### Are GLP-1 drugs safe for long-term use? Yes, GLP-1 medications have been studied extensively and are approved for long-term use by regulatory agencies. Like any medication, they should be used under medical supervision with regular monitoring and follow-up. #### What is the cost of GLP-1 therapy? Costs vary depending on the specific medication, insurance coverage, and pharmacy pricing. Many insurance plans now cover GLP-1 medications for both diabetes and weight loss, though some patients may need to explore patient assistance programs. #### How does GLP-1 therapy compare to weight loss surgery? GLP-1 therapy is less invasive than bariatric surgery and does not require recovery time, but it typically produces more modest weight loss than surgical approaches. Your doctor can help you decide which option best fits your medical situation and preferences. #### Will my weight loss be permanent after GLP-1 treatment? Weight loss can be maintained long-term if you continue the medication and maintain healthy lifestyle changes like diet and exercise. Many patients find that stopping the medication leads to weight regain, which is why ongoing treatment is often recommended. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [GLP-1 Weight Loss: Semaglutide vs Tirzepatide Evidence](https://cedclinic.com/semaglutide-vs-tirzepatide-cardiovascular-outcomes/) Compare clinical evidence on weight loss efficacy between Semaglutide and Tirzepatide GLP-1 therapies. [Read More](https://cedclinic.com/semaglutide-vs-tirzepatide-cardiovascular-outcomes/) [GLP-1 Weight Loss Injections: Clinical Evidence and Safety](https://cedclinic.com/glp-1-receptor-agonist-ocular-safety-clinical-evidence/) Review safety profiles and clinical outcomes of GLP-1 weight loss injections for informed treatment decisions. [Explore Details](https://cedclinic.com/glp-1-receptor-agonist-ocular-safety-clinical-evidence/) [GLP-1 Receptor Agonist Side Effects and Safety Profile](https://cedclinic.com/glp-1-receptor-agonist-thermoregulatory-symptoms/) Understand common [side effects](https://cedclinic.com/cannabis-intoxication-memory-disruption/) and safety considerations for GLP-1 receptor agonist therapies. [Learn More](https://cedclinic.com/glp-1-receptor-agonist-thermoregulatory-symptoms/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).